Octavio Ramilo, MD

Chair
St. Jude Children's Research Hospital
Memphis, TN, United States

Disclosure(s): Pfizer, Sanofi, Gates Foundation, NIH, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD): Advisor/Consultant, Grant/Research Support, Honoraria, SAC member for MSD

Presentation(s):

• 166 - A Phase 2b/3 Study to Evaluate the Efficacy and Safety of an Investigational Respiratory Syncytial Virus (RSV) Antibody, Clesrovimab, in Healthy Preterm and Full-Term Infants

  Thursday, October 17, 2024
  2:09 PM – 2:21 PM US PT

• 167 - Phase 3, Randomized, Controlled Trial Evaluating Safety, Efficacy, and Pharmacokinetics (PK) of Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease

  Thursday, October 17, 2024
  2:21 PM – 2:33 PM US PT

• 518 - Newborn immune transcriptome changes rapidly and is shaped by maternal SARS-CoV-2 infection and/or vaccination

  Saturday, October 19, 2024
  11:15 AM – 11:30 AM US PT